Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
暂无分享,去创建一个
A. Jankowska | M. McDevitt | C. O'keefe | J. Maciejewski | Y. Saunthararajah | Y. Sugimoto | R. Mahfouz | M. Sekeres | H. Makishima | N. Hosono | B. Przychodzen | Zhenbo Hu | S. Vatolin | F. Reu | A. Moliterno | A. List | V. Cheriyath | A. List | A. Dunbar | S. Khan | R. Mahfouz | Z. Hu | S. Khan
[1] S. Vatolin,et al. Direct Chromatin PCR (DC-PCR): Hypotonic Conditions Allow Differentiation of Chromatin States during Thermal Cycling , 2012, PloS one.
[2] Christopher J. Schofield,et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.
[3] A. Jankowska,et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. , 2012, Blood.
[4] Bob Löwenberg,et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. , 2012, Blood.
[5] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[6] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[7] K. Döhner,et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. , 2012, Blood.
[8] P. Guglielmelli,et al. EZH2 mutational status predicts poor survival in myelofibrosis. , 2011, Blood.
[9] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[10] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[11] A. Jankowska,et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. , 2011, Blood.
[12] M. Cazzola,et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. , 2011, Blood.
[13] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[14] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Gribben,et al. EZH2 Y641 mutations in follicular lymphoma , 2011, Leukemia.
[16] J. Maciejewski,et al. Updates in Cytogenetics and Molecular Markers in MDS , 2011, Current hematologic malignancy reports.
[17] A. Kohlmann,et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance , 2011, Leukemia.
[18] Ayalew Tefferi,et al. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Gilliland,et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[20] O. Elemento,et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.
[21] A. Jankowska,et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.
[22] D. Birnbaum,et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia , 2010, British journal of haematology.
[23] Guy Sauvageau,et al. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.
[24] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[25] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[26] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[27] A. Iwama,et al. Role of the polycomb group proteins in hematopoietic stem cells , 2010, Development, growth & differentiation.
[28] L. Gondek,et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). , 2010, Leukemia research.
[29] Ryan D. Morin,et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.
[30] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[31] H. Zentgraf,et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells , 2008, International journal of cancer.
[32] Y. Kotake,et al. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. , 2007, Genes & development.
[33] Kristian Helin,et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.
[34] M. Hung,et al. Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.
[35] Yi Zhang,et al. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.
[36] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[38] M. Surani,et al. The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development , 2001, Molecular and Cellular Biology.
[39] Unnur Thorsteinsdottir,et al. Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia , 2001, Molecular and Cellular Biology.
[40] K. Calvo,et al. Hoxa9 Immortalizes a Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Promyelocyte Capable of Biphenotypic Differentiation to Neutrophils or Macrophages, Independent of Enforced Meis Expression , 2000, Molecular and Cellular Biology.
[41] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[42] S. Scherer,et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. , 1998, Blood.
[43] C. Nislow,et al. Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.
[44] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[45] S. Antonarakis,et al. Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. , 1996, Genomics.